We are live on
!
Find out more
OPPM
Opus Point Partners Management Portfolio holdings
AUM
$55.3M
1-Year Est. Return
7.48%
This Fund
S&P 500
This Quarter
Est. Return
+11.44%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$46.1M
AUM Growth
-$4.88M
(-9.6%)
Cap. Flow
-$2.83M
Cap. Flow
% of AUM
-6.15%
Top 10 Holdings %
Top 10 Hldgs %
52.4%
Holding
53
New
2
Increased
15
Reduced
16
Closed
3
Avg Time Held Equity + Options
8.3
quarters
Top 10 Avg Time Held Equity + Options
2.1
quarters
Top 20 Avg Time Held Equity + Options
4
quarters
Avg Time Held Equity only
8.3
quarters
Top 10 Avg Time Held Equity only
3.1
quarters
Top 20 Avg Time Held Equity only
4.7
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$3.14M |
| 2 |
Lite Strategy Inc
LITS
|
+$1.23M |
| 3 |
Exelixis
EXEL
|
+$280K |
| 4 |
Incyte
INCY
|
+$71.3K |
| 5 |
Alkermes
ALKS
|
+$55.5K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
+$5.11M |
| 2 |
Nektar Therapeutics
NKTR
|
+$1.15M |
| 3 |
Karyopharm Therapeutics
KPTI
|
+$671K |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$382K |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$281K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.92% |
| 2 | Miscellaneous | 28.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
State Street SPDR S&P Biotech ETF
XBI
$10B
| $5.52M | 11.97% |
58,000
+34,200
| +144% | +$3.14M |
2016 Q2
8 quarters
|
|
|
2
ProShares Ultra NASDAQ Biotechnology
BIB
$91.6M
| $5.37M | 11.64% |
93,805
-93,805
| -50% | -$5.11M |
2016 Q3
7 quarters
|
|
3
Mettler-Toledo International
MTD
$31.3B
| $2.08M | 4.51% |
3,594
| – | – |
2014 Q4
14 quarters
|
|
4
iShares Biotechnology ETF
IBB
$10.5B
| $2.06M | 4.47% |
18,750
| – | – |
2016 Q2
8 quarters
|
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.71M | 3.7% |
13,734
-119
| -0.9% | -$13.9K |
2014 Q4
14 quarters
|
|
6
Vertex Pharmaceuticals
VRTX
$129B
| $1.59M | 3.44% |
9,331
+107
| +1% | +$16.6K |
2014 Q4
14 quarters
|
|
|
7
Lite Strategy Inc
LITS
$37.4M
| $1.58M | 3.42% |
+20,000
| New | +$1.23M |
2018 Q2
0 quarters
|
|
8
Illumina
ILMN
$41B
| $1.5M | 3.24% |
5,502
-158
| -3% | -$40.2K |
2014 Q4
14 quarters
|
|
9
Alnylam Pharmaceuticals
ALNY
$30.5B
| $1.39M | 3.01% |
14,112
+432
| +3% | +$42.8K |
2014 Q4
14 quarters
|
|
|
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.38M | 3% |
20,834
-292
| -1% | -$16.7K |
2014 Q4
14 quarters
|
|
11
Agios Pharmaceuticals
AGIO
$1.85B
| $1.33M | 2.89% |
15,833
-169
| -1% | -$14.7K |
2015 Q3
11 quarters
|
|
|
LOXO
12
DELISTED
Loxo Oncology, Inc
LOXO
| $1.2M | 2.6% |
6,900
| – | – |
2017 Q2
4 quarters
|
|
13
Qiagen
QGEN
$9.32B
| $1.18M | 2.57% |
30,857
-419
| -1% | -$15.4K |
2017 Q1
5 quarters
|
|
14
Kyntra Bio
KYNB
$24.3M
| $1.15M | 2.5% |
737
+6
| +0.8% | +$7.82K |
2017 Q4
2 quarters
|
|
15
ProQR Therapeutics
PRQR
$220M
| $1.12M | 2.44% |
153,846
| – | – |
2017 Q4
2 quarters
|
|
16
Amgen
AMGN
$224B
| $1.09M | 2.37% |
5,930
+125
| +2% | +$22.1K |
2014 Q4
14 quarters
|
|
|
17
Alkermes
ALKS
$6.74B
| $1.05M | 2.28% |
25,552
+1,219
| +5% | +$55.5K |
2014 Q4
14 quarters
|
|
18
Biogen
BIIB
$34.6B
| $1.02M | 2.22% |
3,532
+15
| +0.4% | +$4.22K |
2014 Q4
14 quarters
|
|
19
Ionis Pharmaceuticals
IONS
$7.34B
| $997K | 2.16% |
23,916
+783
| +3% | +$34.7K |
2014 Q4
14 quarters
|
|
20
BioMarin Pharmaceuticals
BMRN
$10.8B
| $974K | 2.11% |
10,336
-320
| -3% | -$28K |
2014 Q4
14 quarters
|
|
21
Regeneron Pharmaceuticals
REGN
$78.8B
| $931K | 2.02% |
2,698
+76
| +3% | +$23.8K |
2014 Q4
14 quarters
|
|
|
22
Incyte
INCY
$22.8B
| $826K | 1.79% |
12,321
+1,043
| +9% | +$71.3K |
2014 Q4
14 quarters
|
|
|
CELG
23
DELISTED
Celgene Corp
CELG
| $772K | 1.67% |
9,724
+212
| +2% | +$17.6K |
2014 Q4
14 quarters
|
|
|
CLVS
24
DELISTED
Clovis Oncology, Inc.
CLVS
| $591K | 1.28% |
13,000
| – | – |
2016 Q4
6 quarters
|
|
|
TSRO
25
DELISTED
TESARO, Inc.
TSRO
| $511K | 1.11% |
11,500
| – | – |
2016 Q4
6 quarters
|
|
Similar funds
KIA
PGA
GX
SCG
TCMV
FCM
DP
SAM
Opus Point Partners Management's Q2 2018 Portfolio in Review
As of Q2 2018, Opus Point Partners Management held 53 positions worth $46.1M, down 9.6% from $51M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Opus Point Partners Management withdrew a net $2.83M in Q2 2018, closing 3 positions and reducing 16 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $671K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 65% a quarter earlier, followed by Miscellaneous.
Against the trend, Opus Point Partners Management opened a new position in Lite Strategy Inc worth $1.58M.
- Opus Point Partners Management's largest Q2 2018 buy was Lite Strategy Inc: 20,000 shares worth $1.58M.
- Opus Point Partners Management added most to State Street SPDR S&P Biotech ETF in Q2 2018, an estimated $3.14M increase.
- Opus Point Partners Management's biggest Q2 2018 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $5.11M.
- Opus Point Partners Management fully exited Karyopharm Therapeutics in Q2 2018, selling an estimated $671K.
- Opus Point Partners Management's ten largest holdings make up 52% of its $46.1M portfolio in Q2 2018.
- Opus Point Partners Management opened 2 new positions and closed 3 in Q2 2018.
- Opus Point Partners Management's portfolio value fell 9.6% quarter-over-quarter to $46.1M.
Based on Opus Point Partners Management's 13F filing for Q2 2018, filed 14 Aug 2018.